| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1920.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Clinical Trials Research Unit (C.S.A., K.N.C., W.J.B., M.L.H.), Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; the Section of Epidemiology and Biostatistics (J.B.B.), School of Population Health, University of Auckland, Auckland, New Zealand; and Non-Communicable Disease and Mental Health (R.B.), World Health Organization, Geneva, Switzerland.
Correspondence to Professor Craig Anderson, Clinical Trials Research Unit, The University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail c.anderson{at}ctru.auckland.ac.nz
| Abstract |
|---|
|
|
|---|
Methods During 12 months beginning March 1, 1981, half of all residents of Auckland with acute first-ever or recurrent stroke (n=680) were assessed and followed up prospectively during the next 2 decades. In 2002, their vital status and health-related quality of life (HRQoL) using the 36-item short-form questionnaire (SF-36) were determined by telephone interviews. KaplanMeier survival probabilities for the stroke cohort were compared with life table estimates for the New Zealand population. The SF-36 profile of 21-year stroke survivors was compared with a standardized New Zealand population.
Results Overall, 626 of the original cohort had died and 4 were lost to follow-up, leaving 50 (7%) individuals (57% male; mean age 70 years) available in 2002, of whom 12% were residents of an institutional care facility and 19% required help with everyday activities. The stroke cohort had nearly twice the mortality rate of the New Zealand population, but the SF-36 profile of very long-term stroke survivors was broadly similar to the general population.
Conclusions Because stroke is generally a disease of older people and has a high case fatality, it is not surprising that <1 in 10 people survive 2 decades after onset. However, of those who do, their HRQoL profile suggests that they meld relatively successfully within the general population, despite ongoing disability and a higher mortality risk.
Key Words: stroke outcome survival quality of life
| Introduction |
|---|
|
|
|---|
20 years after first stroke.14 Yet, the unique nature of this cohort and the small numbers (only 10 people were included at the end of follow-up) limit the ability to generalize the data. Because stroke is often part of a chronic disease process, with survivors facing high risks of recurrent vascular events and ongoing morbidity, it is important for health care planning, both preventative and therapeutic, that more information is obtained on long-term stroke outcome in different populations. In this study, we aimed to follow up all stroke patients who participated in the first Auckland Region Coronary Or Stroke (ARCOS) Study of 1981 to 198215 to (1) compare survival after stroke with life expectancy among individuals of the same age and sex in New Zealand; and (2) assess physical functioning and compare the health-related quality of life (HRQoL) of 21-year survivors with that of national age- and sex-standardized normal values.
| Subjects and Methods |
|---|
|
|
|---|
Baseline Assessment and Follow-Up
Baseline data collected through structured in-person interviews with subjects (or proxy) using standardized questionnaires included sociodemographic characteristics; risk factors, including smoking status and previous history of stroke, high blood pressure (hypertension), diabetes mellitus, and heart attack; and clinical features and management of the stroke. Cases with sufficient data were classified into the major stroke subtypes of cerebral infarction, subarachnoid hemorrhage (SAH) or intracerebral hemorrhage.
All subjects (n=74) not known to have died at the 16-year follow-up assessment in 1997, and who had agreed to subsequent contact, were included in the current study. Contact was initiated, principally by telephone, for subjects who were thought to be alive. After gaining informed consent, a structured telephone interview was conducted with either the subject or a reliable proxy, usually the spouse. For those people for whom previous contact details were out of date, exhaustive attempts were made to locate them using telephone directories, electoral rolls, and by contacting relatives, with final checks of vital status being made through the New Zealand Health Information Service for those people who could not be contacted.
At follow-up, information was collected on living arrangements and whether the subject required help with everyday activities of daily living (ADL). The 36-item short-form questionnaire (SF-36) was used to assess HRQoL. The SF-36 has been validated for use in stroke patients17,18 and comprises 36 questions covering 8 domains: physical functioning (PF), role limitations resulting from physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations attributable to emotional problems (RE), and mental health (MH). An absence of problems in a domain is indicated by a score of 100 for the PF, RP, BP, SF, and RE domains, and of 50 for the GH, VT, and MH domains. For example, a score of 100 in PF indicates an ability to perform all activities without limitations because of ill health, whereas a score of 50 in MH indicates an ability to function without personal or emotional problems. To obtain scores of >50 for GH, VT, and MH, a subject must rate his/her health positively, for example, a score of 100 in MH would indicate that the subject feels "peaceful and happy and is calm all the time." Scores for the SF-36 are available for the New Zealand population, including Maori people, enabling age and sex comparisons with stroke survivors.
Statistical Analysis
Differences in baseline characteristics between subjects who had died and those who survived for 21 years were examined with the
2 test for categorical variables and a t test for continuous variables. The KaplanMeier product-limit method was used to generate survival P values and curves for the ARCOS cohort on the basis of date of death and censoring for individuals lost to follow-up using the date of last assessment. These data were compared with life table survival estimates for the general New Zealand population (>45 years old) on the basis of the 1981 Census and subsequent 5 yearly official mortality statistics, with adjustments made for the older age and different sex structure of the ARCOS Study population. SF-36 domain scores and SEs were calculated according to standard guidelines19,20 and analyzed using standard parametric methods. Crude mean SF-36 scores for stroke survivors were compared with age and sex standardized New Zealand normal values.20 All data were analyzed using SAS for Windows (SAS Institute)21 and reported with 95% CIs.
| Results |
|---|
|
|
|---|
Table 1 shows the baseline characteristics of all the ARCOS participants and of the 626 deceased subjects compared with the 54 survivors at 21 years. Very long-term survivors were significantly younger, had less premorbid dependency, were more likely to have smoked but less likely to have had diabetes, and their strokes were less disabling, more often a first-ever event, and attributable to SAH at onset.
|
Table 2 shows that of the 50 survivors interviewed (age mean±SD; 70±13 years; 56% male), more than half considered themselves to have made a full recovery from their stroke. Only one fifth of survivors, all of whom were previously independent, said they required help with ADL, which was considered by all but 1 to be caused by the effects of stroke. However, only 6 of the 9 dependent individuals were residents of a long-term institutional care facility; they tended to be older (mean age 78 years) and female.
|
Figure 1 shows the KaplanMeier estimates for the stroke cohort against the adjusted national life table estimates from 1981, with the curves continuing to diverge at the end of follow-up. On average, the stroke cohort had a 70% greater risk of dying than individuals of the same age and sex in the general population. The risk of death was greatest (double) during the first 5 years after the onset of stroke, attenuating to 17% above that of the natural mortality curve of the general population by 2001.
|
SF-36 data were available for 48 (96%) survivors and are summarized in Table 2. The crude mean scores for the GH, MH, and VT domains were all >50, indicating that the group evaluated their health "positively." Figure 2 shows the standardized mean SF-36 scores of survivors compared with the New Zealand population. With the exception of the VT domain, there were no significant differences in SF-36 profiles. Because the standardized scores were based on noninstitutionalized people, we performed a second comparative analysis excluding the 6 institutionalized stroke survivors and produced similar findings (data not shown).
|
| Discussion |
|---|
|
|
|---|
A major strength of this study was the prospective population-based design that is regarded as having fulfilled most of the stringent criteria required for an "ideal" stroke incidence study22,23 and for an outcome study.24 In particular, the study used established clinical diagnostic criteria and standardized measures and procedures to ensure completeness in ascertainment of a representative sample of stroke cases in a large, well-defined population and the near-complete follow-up of cases from early to 21 years after stroke onset.
However, we acknowledge some limitations to the study. First, different methods were used for the survival analyses: KaplanMeier survival estimates for the ARCOS Study cohort and life tables for the New Zealand population because survival data were not available specifically for the population of Auckland. Despite our efforts to minimize any differences in the structure of these 2 populations by using life table estimates only for people
45 years old and by making further adjustments for the age and sex structure of the ARCOS Study population, there is the likelihood of bias being introduced in these analyses. However, we believe that any such bias is likely to be small because the sociodemographic structure of the Auckland and New Zealand populations as a whole were very similar in 1981, and both analyses included similar periods of inclusion and observation for individuals, thus taking into account the potential important period effects on survival.25 Although there are small numbers toward the tails of the curves, especially for the stroke cohort, the shapes of the curves are different and will not converge until all people have died in both cohorts, indicating that stroke patients continue to have a higher risk of death even after
20 years. Another limiting factor is the small number of subjects included in the assessment of HRQoL. Although there was more than 80% power to detect 10-point differences between groups across most of the 8 domains on the SF-36, the sample was too small to detect smaller but more clinically significant reductions in HRQoL among very long-term stroke survivors.
Our findings compare favorably with the limited number of other reports on the long-term prognosis of stroke. Cumulative case fatalities have been estimated at 40% to 60% at 5 years4,10,26 and >80% at 14 years after acute stroke in a hospital-based series from Linkoping, Sweden,8 and a community-based study in Helsinki, Finland.7 The latter study also found that nearly all long-term stroke survivors who continued to live at home were free of stroke-related disabilities. The study with the longest period of follow-up is from Framingham, Mass, where people who experienced strokes between 1972 and 1974 were assessed biennially for >3 decades.14 At the end of the follow-up period (mean time 27.4 years), only 9 (6% of 147) individuals remained alive; 8 were independent in ADL, and only 1 required institutional care. The higher proportion (19%) of survivors with ongoing dependency in ADL in our study may reflect differences in the assessment methods, but it may also be related to differences in case mix and the health care and social support systems in the 2 populations. Imprecision of the estimates because of the small numbers of subjects in both studies also limit the conclusions that can be drawn.
The population-based study that is most similar to the ARCOS Study is the Perth Community Stroke Study,12 which reported recently that approximately one fifth of stroke patients survived for 10 years, and 1-year survivors experienced an average annual case fatality of
5%, which was twice that of the population of Western Australia. We were not able to obtain cause-specific mortality data for the ARCOS cohort to confirm whether there is a similar high and ongoing risk of death from cardiovascular disease to that in the Perth study.
Survival is clearly the most fundamental measure of stroke outcome, the magnitude of the prevalent burden of stroke being influenced strongly in case fatality or life expectancy ratios to that of the general population. In the acute phase, the chance of surviving a stroke is generally a complex function of the extent of cerebral damage and the complications of disability, whereas in the longer term, age, sex, and continued exposure to vascular risk factors influence survival. To what extent positive trends in survival after stroke are related to advances in initial treatment and secondary prevention remains to be adequately elucidated.27
In conclusion, our data reaffirm the high early and ongoing risk of death among stroke patients, but they also suggest that functioning and HRQoL of those patients who survive
2 decades are comparable to that of the general population. These data are likely to reflect a better life expectancy for healthier people given certain favorable characteristics, including effects of illness at onset, among the very long-term stroke survivors of the ARCOS cohort. Thus, although it could be argued that stroke survivors are never truly free of effects of stroke, our data could also be viewed positively in the ability of many people to readjust, given sufficient time, to residual and often considerable stroke-related disability.
| Acknowledgments |
|---|
Received February 22, 2004; revision received April 4, 2004; accepted May 2, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I. Muus, L. S. Williams, and K. C. Ringsberg Validation of the Stroke Specific Quality of Life Scale (SS-QOL): test of reliability and validity of the Danish version (SS-QOL-DK) Clinical Rehabilitation, July 1, 2007; 21(7): 620 - 627. [Abstract] [PDF] |
||||
![]() |
I van Wijk, E Lindeman, L J Kappelle, J van Gijn, P J Koudstaal, J W Gorter, A Algra, and for the LiLAC Study Group* Functional status and use of healthcare facilities in long-term survivors of transient ischaemic attack or minor ischaemic stroke J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1238 - 1243. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |